News Bites

From scientific findings to organizational highlights, peruse a wide assortment of updates and announcements.

Our Season of Giving Challenge

Our Season of Giving Challenge

12.20.24– Letter from Co-Founder & President, David Fajgenbaum

iMCD Symtom Burden Scale

iMCD Symtom Burden Scale

If you are living with idiopathic multicentric Castleman Disease (iMCD), we need your help!

Our Season of Giving Challenge

Our Season of Giving Challenge

11.23.24 – Letter from Executive Director, Mary Zuccato

Idiopathic multicentric Castleman disease with marrow fibrosis and extramedullary hematopoiesis

Idiopathic multicentric Castleman disease with marrow fibrosis and extramedullary hematopoiesis

Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease

Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease

Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease

Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease

Siltuximab administration results in spurious IL-6 elevation in peripheral blood

Siltuximab administration results in spurious IL-6 elevation in peripheral blood

Symptom burden in patients with iMCD

Ongoing symptoms following complete surgical excision in UCD

Ongoing symptoms following complete surgical excision in UCD

Treatment Consistent with Idiopathic Multicentric Castleman Disease Guidelines is Associated with Improved Outcomes

Treatment Consistent with Idiopathic Multicentric Castleman Disease Guidelines is Associated with Improved Outcomes

$A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD$

A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD

All In Movement (AIM) Publication

All In Movement (AIM) Publication

CXCL13 is a predictive biomarker in iMCD

CXCL13 is a predictive biomarker in iMCD

The lymph node transcriptome of UCD and iMCD

The lymph node transcriptome of UCD and iMCD

How We Manage iMCD

How We Manage iMCD

Organ dysfunction, thrombotic events and malignancies in patients with iMCD

Organ dysfunction, thrombotic events and malignancies in patients with iMCD

Optimization of anti-IL6 therapy

Optimization of anti-IL6 therapy

Siltuximab is associated with improved progression-free survival in iMCD

Siltuximab is associated with improved progression-free survival in iMCD

Global public awareness of CD and TAFRO: A Google Trends analysis

Global public awareness of CD and TAFRO: A Google Trends analysis

Transcriptome and unique cytokine microenvironment of CD

Transcriptome and unique cytokine microenvironment of CD

The disease course of CD patients with fatal outcomes published in BJHaem

The disease course of CD patients with fatal outcomes published in BJHaem

Castleman Disease: Pearls and Myths

Castleman Disease: Pearls and Myths

Discovery of Increased mTORC2 pathway activation published in Journal of Cellular and Molecular Medicine

Discovery of Increased mTORC2 pathway activation published in Journal of Cellular and Molecular Medicine

Bone marrow findings of iMCD published in Hematological Oncology

Bone marrow findings of iMCD published in Hematological Oncology

CDCN study presented at the American Society of Clinical Oncology Meeting

CDCN study presented at the American Society of Clinical Oncology Meeting

CDCN Contributes 7 Abstracts to 2021 American Society of Hematology Conference

CDCN Contributes 7 Abstracts to 2021 American Society of Hematology Conference

Discovery of genetic factors for susceptibility to iMCD published in Journal of Experimental Medicine

Discovery of genetic factors for susceptibility to iMCD published in Journal of Experimental Medicine

The Critical Role of Pathology in the Diagnosis of Castleman Disease

The Critical Role of Pathology in the Diagnosis of Castleman Disease

Pharmacy Perspectives: Optimizing Treatment of Idiopathic Multicentric Castleman Disease

Pharmacy Perspectives: Optimizing Treatment of Idiopathic Multicentric Castleman Disease

Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease

Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease

New Chinese Castleman Disease Network holds launch meeting

New Chinese Castleman Disease Network holds launch meeting

ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder

ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder

Guidance from the CDCN Scientific Advisory Board members on COVID-19 vaccination for Castleman disease patients

Updates in the Diagnosis and Treatment of Castleman Disease: Expert Perspectives

Updates in the Diagnosis and Treatment of Castleman Disease: Expert Perspectives

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman Disease

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman Disease

Diagnosis and treatment of Castleman disease: The role of the oncology nurse

Diagnosis and treatment of Castleman disease: The role of the oncology nurse

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

Chasing My Cure

Chasing My Cure

Increased mTOR activation in idiopathic multicentric Castleman disease

Increased mTOR activation in idiopathic multicentric Castleman disease

Potential Genetic Contributors in iMCD-TAFRO Published in Oncogene

Potential Genetic Contributors in iMCD-TAFRO Published in Oncogene

Learn how the CDCN is helping in the fight against COVID19

Learn how the CDCN is helping in the fight against COVID19

Check out some of our top priorities for 2020

Check out some of our top priorities for 2020

Overview of Castleman disease Published in High-Impact Medicine Journal

Overview of Castleman disease Published in High-Impact Medicine Journal

CDCN study one of 64 leading innovations in medicine

CDCN study one of 64 leading innovations in medicine

Open letter regarding COVID-19 from the CDCN Scientific Advisory Board

Open letter regarding COVID-19 from the CDCN Scientific Advisory Board

Newsletter Archive

Newsletter Archive

2019 CDCN Highlights

2019 CDCN Highlights

CDCN at the 2019 ASH Conference

CDCN at the 2019 ASH Conference

July 23 is World Castleman Disease Day

July 23 is World Castleman Disease Day

Genetic mutations identified in unicentric Castleman disease

Genetic mutations identified in unicentric Castleman disease

Press Release: CDCN Partners with CZI

Press Release: CDCN Partners with CZI

First CD Genome Project Data Publicly Available

First CD Genome Project Data Publicly Available

CDCN Publishes on the Collaborative Network Approach

CDCN Publishes on the Collaborative Network Approach

2018 CDCN Highlights

2018 CDCN Highlights

CDCN Research Identifies Lab Tests Predictive of Siltuximab Response in iMCD

CDCN Research Identifies Lab Tests Predictive of Siltuximab Response in iMCD

Fourth Annual Quest for a Cure

Fourth Annual Quest for a Cure

CDCN at the 2018 ASH Conference

CDCN at the 2018 ASH Conference

5th Annual Patient & Loved One Summit

5th Annual Patient & Loved One Summit

First-Ever Treatment Guidelines for Idiopathic Multicentric Castleman Disease

First-Ever Treatment Guidelines for Idiopathic Multicentric Castleman Disease

New French Reference Center for Castleman disease holds Launch Meeting

New French Reference Center for Castleman disease holds Launch Meeting

Patient-Funded Research Reveals Critical New Info about CD

Patient-Funded Research Reveals Critical New Info about CD

CDCN Funds Four High-Impact Grants

CDCN Funds Four High-Impact Grants

Forbes Healthcare Summit 2017

Forbes Healthcare Summit 2017

Patient-Driven Research Questions Answered

Patient-Driven Research Questions Answered

The CDCN Has Been Busy!

The CDCN Has Been Busy!

Dr. Alexander Fossa Contributes Samples Enabling Three High-Impact Studies!

Dr. Alexander Fossa Contributes Samples Enabling Three High-Impact Studies!

CDCN Publishes Four Papers in High-Impact, International Journals

CDCN Publishes Four Papers in High-Impact, International Journals

Wharton Community Enables Genomics Study which is Now Accepting Applications

Wharton Community Enables Genomics Study which is Now Accepting Applications

Patients Contribute Samples and Funding to Enable a Groundbreaking Study

Patients Contribute Samples and Funding to Enable a Groundbreaking Study

CDCN Hosts International CD Pathology Preceptorship with Experts from Latin America

CDCN Hosts International CD Pathology Preceptorship with Experts from Latin America

Co-Founder & Executive Director Named to Forbes 30 Under 30

Co-Founder & Executive Director Named to Forbes 30 Under 30

CDCN Presents at HEMO in Brazil

CDCN Presents at HEMO in Brazil

CDCN Researchers Publish Article on MCD Classification

CDCN Researchers Publish Article on MCD Classification

Board President Greg Pacheco’s Fight Against Castleman Disease

Board President Greg Pacheco’s Fight Against Castleman Disease

CDCN Leads the Way Toward a Cure with an Innovative Collaborative Approach

CDCN Leads the Way Toward a Cure with an Innovative Collaborative Approach